Yukiko Ishikawa-Takemura

Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models

Yoshikazu Fujimori, Kenji Katsuno, Ikumi Nakashima et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 219 citations

KGA-2727, a Novel Selective Inhibitor of a High-Affinity Sodium Glucose Cotransporter (SGLT1), Exhibits Antidiabetic Efficacy in Rodent Models

Toshihide Shibazaki, Masaki Tomae, Yukiko Ishikawa-Takemura et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 81 citations

Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats

Yoshikazu Fujimori, Kenji Katsuno, Kazuma Ojima et al. · European Journal of Pharmacology · 2009 · 70 citations

Metabolic Syndrome, Diabetes Management, Selective Sglt2 Inhibitor +9

Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-Ay mice

Kenji Katsuno, Yoshikazu Fujimori, Yukiko Ishikawa-Takemura et al. · European Journal of Pharmacology · 2009 · 33 citations

Metabolic Syndrome, Diabetes Management, Biochemistry +12

Structure–activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia

Nobuhiko Fushimi, Hideki Fujikura, Hiroaki Shiohara et al. · Bioorganic & Medicinal Chemistry · 2012 · 19 citations · Full text

Pharmaceutical Science, Biochemistry, Medicine +9